Nigrosome-1 neuromelanin-iron coupling profiles in idiopathic and GBA -associated Parkinson’s disease

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Firstly, to determine whether iron-sensitive MRI measures mediate neuromelanin (NM) loss within the substantia nigra pars compacta (SNc) and its subregion, nigrosome-1 (N1) in idiopathic Parkinson’s disease (iPD) and GBA -associated Parkinson’s disease (GBA-PD) versus healthy controls (HC). Secondly, to assess the diagnostic value of NM-and iron MRI metrics, including their lateralisation.

Methods

Eighty-six participants (HC=30, iPD = 30, GBA-PD = 26) underwent midbrain quantitative NM-MRI and susceptibility-weighted imaging (SWI). Contrast ratio (CR), normalised volume (nVol) and left-right asymmetry indices (AI) of SNc and N1 calculated. Receiver-operating analyses assessed group discrimination and onset-side prediction. Bidirectional causal mediation (5,000 bootstraps, FDR-corrected) tested Iron→NM→group and NM→Iron→group pathways. Moderation models examined the effect of GBA-mutation severity.

Results

iPD and GBA-PD showed marked NM loss and increased iron in SNc/N1, being more prominent in GBA-PD. N1 NM metrics provided the strongest discrimination (HC vs GBA-PD AUC=0.93, HC vs iPD AUC=0.83), followed by iron measures (AUC=0.78-0.89). N1 NM asymmetry yielded moderate lateralisation accuracy (AUC=0.76). Cross-sectional mediation analyses identified significant Iron→NM→group effects across SNc and N1 (q<0.01), supporting mechanistic hypotheses of iron-driven NM depletion in PD. In GBA-PD, NM-iron coupling in N1 was influenced by mutation severity, suggesting a genotype-specific disruption of NM-iron homeostasis.

Conclusions

Multi-contrast MRI centered on N1 reveals an iron-driven NM imbalance that distinguishes PD from controls and it is modulated by GBA mutation severity, supporting the applicability of N1-focused NM-iron imaging as a biomarker for PD diagnosis.

Note: This manuscript has been submitted to Journal of Neurology, Neurosurgery & Psychiatry for consideration.

Article activity feed